Skip to main content

Rituximab and hyaluronidase human

Details of the Drug
Generic Name:
Rituximab and hyaluronidase human
ri-TUK-si-mab & hye-al-yoor-ON-i-dase
How the Drug is Given:

Monoclonal antibody

Rituxan Hycela®
Rituximab and hyaluronidase human

Indications and Usage

Rituximab and hyaluronidase human is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:

  • Follicular Lymphoma (FL)
    • Relapsed or refractory, follicular lymphoma as a single agent
    • Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single agent maintenance therapy
    • Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
  • Diffuse Large B-cell Lymphoma (DLBCL)  
    • Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
  • Chronic Lymphocytic Leukemia (CLL)  
    • Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)

Limitations of Use:

  • Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion.

Side effects needing medical attention

Most common adverse reactions are:  

  • FL: infections, neutropenia, nausea, constipation, cough, and fatigue
  • DLBCL: infections, neutropenia, hair loss, nausea, and anemia
  • CLL: infections, neutropenia, nausea, thrombocytopenia, fever, vomiting, and injection site erythema
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.